PATENT

UTILITY PATENT APPLICATION TRANSMITTAL

(only for new non-provisional applications under 37 CFR §1.53(b))



Mail Stop Patent Application Commissioner of Patents P. O. Box 1450 I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Mail Stop Patent Application, Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on Alexandria, VA 22313-1450 Sir: <u>July 24, 2003</u> Transmitted herewith for filing is the patent application Date of Deposi under 37 CFR 1.53(b) of: Bonnie Stein Signature AVENTIS DOCKET NO.: **DEAV2002/0052US NP** Express Mail No. INVENTORS: Lothar Schwink, et al **Substituted Diaryl Heterocycles,** Proc ss for Their Preparation and Their Use as M dicaments **APPLICATION ELEMENTS** *Fee Transmittal Form (e.g., PTO/SB/17) 1. (Submit an original and a duplicate for fee processing) 114 2. Specification Total Pages (preferred arrangement set forth below) - Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to Microfiche Appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure Total Sheets 3. Drawing(s) (35 U.S.C. 113) 4. Oath or Declaration Total Pages

	application, see 37 CFR §§ 1.63(d)(2) and 1.33(b).								
5.	Power of Attorney a. Newly executed (original or copy)	Total Pages							

Copy from a prior application (37 CFR § 1.63(d))

DELETION OF INVENTOR(S)

b. Copy from a prior application (37 CFR § 1.63(d))

Newly unexecuted (original or copy)

6. Microfiche Computer Program (Appendix)

a.

b.

i.

Application Transmittal Letter Page 2

7.	Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. Computer Readable Copy b. Paper Copy (identical to computer copy) c. Statement verifying identity of above copies
	If a CONTINUING Application, check appropriate box, and supply the requisite information: Continuation Divisional Continuation-in-part of prior application no: , filed , Examiner , Group/Art Unit (The cross reference has been/will be inserted on page one of the specification).
\boxtimes	This application claims the benefit of priority of German Patent Application No. 10233817.5-44, filed July 25, 2002, and the benefit of U.S. Provisional Application No. 60/428877, filed November 25, 2002. (The cross reference has been inserted on page one of the specification).
	Incorporation By Reference (useable if filing a continuation/divisional and a copy of the declaration from the prior application is enclosed.) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
ACC	COMPANYING APPLICATION PARTS
7.	Assignment Papers (cover sheet & document(s))
8.	37 CFR §3.73(b) Statement (when there is an assignee)
9.	Verified English Translation Document (if applicable)
10.	Information Disclosure Copies of IDS Citations Statement (IDS)/PTO-1449
11.	Preliminary Amendment
12.	Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
13.	*Small Entity Statement(s) (PTO/SB/09-12) Statement filed in prior application, Status still proper and desired
14.	Certified Copy of Priority Document(s) German 10233817.5-44 (if foreign priority is claimed)
15.	Other: Application Data Sheet
COF	RRESPONDENCE ADDRESS
\boxtimes	Customer Number or Bar Code Label 005487 PATENT TRADEMARK OFFICE
	Lawrence L. Martin Reg. No. 46.902

Lawrence L. Martin, Reg. No. 46,902 Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-4803
Telefax (908) 231-2626

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

EEE TOANGMITTAL		Complete if Known				
FEE TRANSMITTAL	Application Number	N t Yet Assigned				
f EV 0000	Filing Date	Fil d C ncurrently H rewith				
for FY 2003	First Named Inventor	L thar Schwink, t al				
Patent fees are subject to annual revision.	Examiner Name	To Be Assigned				
Applicant claims small entity status. See 37 CFR 1.27	Group / Art Unit	T B Assigned				
TOTAL AMOUNT OF PAYMENT (\$) 1092.00	Attorney Docket No.	DEAV2002/0052US NP				

METHO	METHOD OF PAYMENT (check all that apply) FEE CALCULATION (continued)							d)						
Check Credit Card Money Other None						3. ADDITIONAL FEES								
Deposit Account						Large Entity		Small Entity						
Deposit Account Number	18-1982					Fee Code	Fee (\$)	Fee Code	Fee (\$)		Fee Description	on	Fee Paid	
Deposit Account		Aventis	Pharmac	euticals Inc.		1051							ļ	
Name The Commissioner is authorized to: (check all that apply)							130	2051	65	Surcharge	e - late filing fee o e - late provisiona			
Charge fee(ated below	⊠ Cre	dit any overpa	yments	1052 1053	· 50 130	2052 1053	25 130	cover she Non-Engli					
Charge any additional fee(s) during the pendency of this application						1812	2,520	1812	2,520	For filing a	request for reex			
Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account						1804	920*	1804	920*	Requestin Examiner	g publication of S action	SIR prior to		
FEE CALCULATION							1,840*	1805	1,840*	Requestin Examiner	g publication of S action	SIR after		
1. BASIC FI			-		F	1251	110	2251	55	Extension	for reply within fi	irst month		
Large Entity Fee Fee Code (\$)	Fee Code	II Entity Fee (\$)	Fee Desci	ription	Fee Paid	1252	410	2252	205	Extension	for reply within s	econd month		
1001 750	2001	375	Utility filing	fee	750.0	1253	930	2253	465	Extension	for reply within the	hird month		
1002 330	2002	165	Design filir	•		1254	1,450	2254	725		for reply within for			
1003 520	2003	260	Plant filing			1255	1970	2255	985		for reply within fi	ifth month		
1004 750	2004	375	Reissue fil	-		1401	320	2401	160	Notice of	Appeal			
1005 160	2005	80	Provisiona	I filing fee	L	1402	320	2402	160	-	ief in support of a	an appeal		
	SU	JBTOTAI	L (1)	(\$)		1403	280	2403	140	Request for	or oral hearing			
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE						1451	1,510	1451	1,510	Petition to proceedin	ition to institute a public use ceeding			
Fee Extra from Fee Claims below Paid						1452	110	2452	55	Petition to	revive - unavoid	able		
Total Claims 2	5	-20**= 5	x [18 =	90	1453	1,300	2453	650	Petition to	Petition to revive - unintentional			
Independent 6		- 3**= 3	3 x	84 =	252	1501	1,300	2501	650	Utility issu	Utility issue fee (or reissue)			
Claims			-			1502	470	2502	235	Design issue fee				
Multiple Depende	nt		Ĺ	=	L	1503	630	2503	315	Plant issu				
Large Entity	Sma	II Entity				1460 1807	130 50	1460 1807	130 50		o the Commissio elated to provisio		—	
Fee Fee	Fee	Fee				1007	30	1607	30	application		nia!	1 1	
Code (\$) 1202 18	Code 2202	(\$) 9	Fee Descr	ription excess of 20		1806	180	1806	180	Submissio	on of Information	Disclosure	<u> </u>	
										Stmt				
1201 84	2201	42	inaepende	nt claims in ex	cess of 3	8021	40	8021	40		each patent ass times number of p			
1203 280	2203	140	Multiple de paid	ependent claim	, if not	1809	750	2809	375	Filing a su	bmission after fir			
1204 84	2204	42	**Reissue	independent ver original pat	ent	1810	750	2810	375	For each a	additional invention			
1205 18	2205	9	**Reissue	claims in exces	ss of	1801	750	2801	375		or Continued Exa			
1 20 and over original patent							900	1802	900	Request for expedited examination of a design application				
SUBTOTAL (2) (\$)342.00						Other fee	(specify)			. g. 4F				
**or number previously paid, if greater; For Reissues, see above						*Reduced by Basic Filing Fee Paid			Paid	SUBTOTAL (3) (\$)				
SUBMITTED BY Complete (If ap								plicable)						
Name (Print/Type) Lawrence L. Martin, Reg. No. 46,902								tration No	. 4	6,902	Telephone	(908) 231-	4803	
Signature Lewnen L. Martin						^					Date	July 24, 2	003	

WARNING: Information in this firm may become public. Credit card information should not be included n this f rm. Pr vide credit card inf rmation and auth rizati n n PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Alexandria, VA 22313. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.